ABLi's Risvodetinib Hits Key Parkinson's Biomarkers, But Path to Approval Remains Unprecedented and High-Risk

ABLi Reports Positive Biomarker Findings for Risvodetinib in Parkinson's

ABLi Therapeutics completed a detailed biomarker analysis of risvodetinib in its Phase II 201 Trial for Parkinson's disease, involving up to 80 participants and covering 7,300 individual metrics. The findings indicate that once-daily risvodetinib impacts several biological processes associated with PD, including a substantial reduction in phosphorylated alpha-synuclein in spinal fluid and blood, and suppression of neuroinflammation markers like NLRP3, IL-1beta, and IL-18. These results suggest a reversal of the disease's biological cascade within 12 weeks and support further investigation of the 100mg and 200mg doses in upcoming studies.

• ABLi Therapeutics conducted a detailed biomarker analysis of risvodetinib in its Phase II 201 Trial for Parkinson's disease, involving up to 80 participants. The study evaluated 7,300 individual metrics and focused on the drug's effect on 11 markers related to neuronal degeneration, mitochondrial function, and neuroinflammation, with participants receiving 50mg, 100mg, or 200mg doses once daily.
• The analysis revealed that risvodetinib substantially reversed the biological cascade of Parkinson's disease within 12 weeks of once-daily treatment. Specifically, the 100mg and 200mg doses significantly reduced levels of phosphorylated alpha-synuclein in spinal fluid, while all doses showed reductions in blood samples. Phosphorylated alpha-synuclein is believed to be a causative agent of human PD.
• Risvodetinib also demonstrated suppression of neuroinflammation indicators, including NOD-like Receptor Family Pyrin Domain Containing 3 (NLRP3), interleukin-1 beta (IL-1beta), and IL-18, reducing them below baseline levels in trial participants. These positive biomarker results support further investigation of the 100mg and 200mg doses in future studies such as BASE, ABILITY, and CAMPD, where ABLi will explore links between biomarker changes and clinical outcomes.

Risvodetinib's c-Abl Inhibition: A Novel Approach to Parkinson's Pathophysiology

Recent research highlights several novel therapeutic targets for Parkinson's disease that move beyond conventional dopaminergic pathways, focusing instead on modulating endogenous protective mechanisms and specific molecular pathways. One area of interest involves systemic modulators like the exercise-induced myokine irisin, which crosses the blood-brain barrier to exert pleiotropic neuroprotective effects, including reduced oxidative stress and neuroinflammation. Similarly, sirtuin 1 (SIRT1), an NAD-dependent histone deacetylase, is being explored for its regulatory roles in mitochondrial biogenesis and oxidative stress responses, with SIRT1 activators showing potential to mitigate neuronal senescence. Bilirubin is also emerging as a dual biomarker and therapeutic target, as its levels correlate with disease severity and it plays a role in modulating neuroinflammation and mitochondrial dysfunction. These targets align with broader life-course prevention strategies that aim to build neurobiological reserves and prevent pro-inflammatory states through interventions like physical activity and cognitive training.

Alongside systemic approaches, highly specific molecular targets are under investigation, offering the potential for precision medicine. Phosphodiesterase 4 (PDE4) inhibitors are being developed as potential disease-modifying therapies due to PDE4's role as the primary hydrolase of cAMP and its involvement in regulating oxidative stress, ferroptosis, and endoplasmic reticulum stress. Development efforts are focused on overcoming challenges in drug selectivity and central permeability through subtype-selective inhibitors and novel delivery systems. In the genetic realm, modulation of Parkin (PRKN) presents a mutation-specific therapeutic opportunity. In patients with homozygous deletion of PRKN Exon 2, an alternative translation initiation event produces a truncated Parkin proteoform that retains partial ubiquitin ligase activity. The investigational modulator BIO-2007817 is designed to enhance the function of this truncated protein, though it requires strict patient stratification by genotype as it can reduce the activity of endogenous full-length Parkin.

ABL Inhibition: A New Frontier in Parkinson's Disease Treatment

The recent biomarker analysis for risvodetinib in Parkinson's disease (PD) represents a potentially transformative moment for the neurodegenerative field. For years, the focus in PD treatment has largely been on managing symptoms, with limited success in altering the disease's underlying progression. The finding that risvodetinib, an ABL kinase inhibitor, can substantially reduce phosphorylated alpha-synuclein and suppress key neuroinflammation markers like NLRP3, IL-1beta, and IL-18 within just 12 weeks is highly encouraging. This suggests a potential for biological reversal of the disease cascade, moving beyond mere symptomatic relief to addressing the root causes of neuronal dysfunction.

ABL kinases are known to play important roles in neuron development, maintenance, and signaling, providing a strong scientific rationale for this therapeutic approach. The ability to demonstrate such clear biomarker changes in spinal fluid and blood offers a powerful tool for guiding future clinical development, potentially accelerating the path to larger, pivotal trials. This early validation of target engagement and biological effect in the central nervous system is invaluable, especially given the historical challenges in developing effective treatments for brain disorders.

However, the journey for ABL kinase inhibitors in neurodegeneration is not without its complexities. The broader class of ABL inhibitors, particularly those developed for oncology, has demonstrated a spectrum of cardiovascular side effects, notably arterial thrombosis with some newer agents. This necessitates careful consideration of the long-term safety profile for a chronic condition like Parkinson's, where patients may be on treatment for many years. Furthermore, while ABL kinases are implicated in neuronal function, and specific inhibitors can be designed to cross the blood-brain barrier (BBB), this is not a universal characteristic of all ABL inhibitors. Ensuring sustained and effective CNS penetration for risvodetinib will be critical for its therapeutic success. The need for continuous ABL kinase inhibition, as observed in preclinical models, also highlights the importance of optimal dosing regimens to maintain therapeutic levels and maximize patient adherence. As risvodetinib progresses, these considerations will be paramount in realizing its full potential.